BCL2 and acute myeloid leukemia: Notably, the BCL‐2 inhibitor venetoclax (ABT‐199) was approved for use in combination with a hypomethylating agent (HMA) or with low‐dose cytarabine (LDAC) for the treatment of newly diagnosed patients with AML who are age 75 years or older or are ineligible for intensive chemotherapy.5, 6